Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Total 13F shares
-
43,068,809
-
Share change
-
+1,872,724
-
Total reported value
-
$1,095,674,563
-
Put/Call ratio
-
29%
-
Price per share
-
$25.44
-
Number of holders
-
134
-
Value change
-
+$40,970,202
-
Number of buys
-
81
-
Number of sells
-
50
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q1 2023
As of 31 Mar 2023,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,068,809 shares.
The largest 10 holders included
BlackRock Inc., VR Adviser, LLC, STATE STREET CORP, COMMODORE CAPITAL LP, VANGUARD GROUP INC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Vivo Capital, LLC, and Fairmount Funds Management LLC.
This page lists
134
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.